Moreillon P, Que YA: Infective endocarditis. Lancet. 2004, 363: 139-149. 10.1016/S0140-6736(03)15266-X.
Article
PubMed
Google Scholar
Mylonakis E, Calderwood SB: Infective endocarditis in adults. N Engl J Med. 2001, 345: 1318-1330. 10.1056/NEJMra010082.
Article
CAS
PubMed
Google Scholar
Fowler VG, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, Corey GR, Spelman D, Bradley SF, Barsic B, et al: Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA. 2005, 293: 3012-3021. 10.1001/jama.293.24.3012.
Article
CAS
PubMed
Google Scholar
Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC: Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997, 40: 135-136. 10.1093/jac/40.1.135.
Article
CAS
PubMed
Google Scholar
Baltz RH: Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr Opin Chem Biol. 2009, 13: 144-151. 10.1016/j.cbpa.2009.02.031.
Article
CAS
PubMed
Google Scholar
Falagas ME, Giannopoulou KP, Ntziora F, Vardakas KZ: Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. J Antimicrob Chemother. 2007, 60: 7-19. 10.1093/jac/dkm137.
Article
CAS
PubMed
Google Scholar
Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, et al: Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006, 355: 653-665. 10.1056/NEJMoa053783.
Article
CAS
PubMed
Google Scholar
Jones T, Yeaman MR, Sakoulas G, Yang SJ, Proctor RA, Sahl HG, Schrenzel J, Xiong YQ, Bayer AS: Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother. 2008, 52: 269-278. 10.1128/AAC.00719-07.
Article
CAS
PubMed
Google Scholar
Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI: Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis. 2008, 46: 1069-1077. 10.1086/527442.
Article
PubMed
Google Scholar
Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME: Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents. 2009, 34: 506-515. 10.1016/j.ijantimicag.2009.08.013.
Article
CAS
PubMed
Google Scholar
Falagas ME, Roussos N, Gkegkes ID, Rafailidis PI, Karageorgopoulos DE: Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin Investig Drugs. 2009, 18: 921-944. 10.1517/13543780902967624.
Article
CAS
PubMed
Google Scholar
Murchan S, Kaufmann ME, Deplano A, de Ryck R, Struelens M, Zinn CE, Fussing V, Salmenlinna S, Vuopio-Varkila J, El Solh N, et al: Harmonization of pulsed-field gel electrophoresis protocols for epidemiological typing of strains of methicillin-resistant Staphylococcus aureus: a single approach developed by consensus in 10 European laboratories and its application for tracing the spread of related strains. J Clin Microbiol. 2003, 41: 1574-1585. 10.1128/JCM.41.4.1574-1585.2003.
Article
CAS
PubMed
PubMed Central
Google Scholar
Steed ME, Vidaillac C, Rybak MJ: Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations. Antimicrob Agents Chemother. 2010, 54: 5187-5192. 10.1128/AAC.00536-10.
Article
CAS
PubMed
PubMed Central
Google Scholar
Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC: Safety and clinical outcomes when utilizing high-dose (> or = 8 mg/kg) daptomycin therapy. Ann Pharmacother. 2009, 43: 1211-1219. 10.1345/aph.1M085.
Article
CAS
PubMed
Google Scholar
Figueroa DA, Mangini E, Amodio-Groton M, Vardianos B, Melchert A, Fana C, Wehbeh W, Urban CM, Segal-Maurer S: Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis. 2009, 49: 177-180. 10.1086/600039.
Article
CAS
PubMed
Google Scholar
Baddour LM, Epstein AE, Erickson CC, Knight BP, Levison ME, Lockhart PB, Masoudi FA, Okum EJ, Wilson WR, Beerman LB, et al: Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation. 2010, 121: 458-477. 10.1161/CIRCULATIONAHA.109.192665.
Article
PubMed
Google Scholar
Baddour LM, Wilson WR, Bayer AS, Fowler VG, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, et al: Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005, 111: e394-434. 10.1161/CIRCULATIONAHA.105.165564.
Article
PubMed
Google Scholar
del Rio A, Anguera I, Miro JM, Mont L, Fowler VG, Azqueta M, Mestres CA: Surgical treatment of pacemaker and defibrillator lead endocarditis: the impact of electrode lead extraction on outcome. Chest. 2003, 124: 1451-1459. 10.1378/chest.124.4.1451.
Article
PubMed
Google Scholar
Comments
View archived comments (1)